Contact us on +44 (0)1270 270010 | info@boydconsultants.com

Our People

Our People

Our experienced team of professionals operate out of our two UK offices and work with clients around the world to support the development of research ideas.

Prof Alan Boyd BSc, MB, ChB, FRSB, PFPM CEO

Professor Alan Boyd began his 30 years’ pharmaceutical career with Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.

In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular he led the development of their gene based medicines portfolio.

In April 2005, he left to set up Boyd Consultants. The focus of which is to aid and support early stage life-science based companies of the sort of which Ark had its origins. His clients now include many companies in Europe, North America and Japan who are devoted to the development of new medicines.

A graduate in Biochemistry and Medicine from the University of Birmingham, UK, Professor Boyd is also a Fellow, and Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK. He was elected President of the Faculty in November 2015, following three years as Vice President.

In November 2009 he was appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development.

Boyd Consultants
Electra House
Crewe Business Park
Crewe, Cheshire
CW1 6GL
T +44 (0)1270 270010
F +44 (0)1270 253832
M +44 (0)7899 873150
E alan.boyd@boydconsultants.com

Dr Julie Warner PhD Director, Regulatory Affairs

Dr Julie Warner completed her PhD in 2002 at the University of Newcastle upon Tyne. After spending some time in research at the University of Cambridge and the biotech company AdProTech, Dr Warner joined Gregory Fryer Associates (GFA) in 2003.

As a Regulatory Consultant at GFA, Dr Warner co-ordinated and managed projects on behalf of clients, ranging from EU and US orphan drug designation applications, to Protocol Assistance/Scientific Advice, multinational clinical trial applications and marketing authorisation applications. During this time, Dr Warner provided strategic and operational regulatory support for the programmes and managed interactions and negotiations with regulatory authorities in both the EU and US.

In 2008, Dr Warner joined Genzyme Europe Research in Cambridge where she was responsible for their cardiovascular portfolio, taking a novel therapy from mid-stage clinical development through to marketing authorisation application.

From there, Dr Warner moved to Clovis Oncology UK and was responsible for preparing and maintaining regulatory submissions for the product portfolio. In 2013, Dr Warner was appointed Senior Regulatory Programme Manager at Roche Products, working on an oncology development project.

Dr Warner joined Boyds in August 2014 to strengthen the existing regulatory affairs team and in 2016, she became Director of Regulatory Affairs. Bringing over 10 years experience in EU and US regulatory affairs, Dr Warner has a special interest in orphan drugs.

Dr Warner has been a member of the Editorial Panel for the professional journal of The Organisation for Professionals in Regulatory Affairs (TOPRA), the Regulatory Rapporteur, for over 10 years, and in 2015 became a Fellow of TOPRA.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7880 200222
E julie.warner@boydconsultants.com

 

Dr Nicholas Meyers PhD Programme Director

Dr Nick Meyers is an experienced Programme Director with over 20 years’ experience within the industry, working in large pharma, biotech and the CRO sector, delivering internally-resourced and out-sourced projects involving multi-disciplinary teams spanning different companies and geographies.

Since moving into industry in the mid-1990s, Nick spent 8 years with SmithKline Beecham leading internal research projects and collaborations with academic groups, working and publishing in a number of diverse fields (e.g., oral microbiology, dermatology, herpetology). This was followed by 12 years working in two small, virtual biotech companies in the UK (Alizyme Therapeutics Ltd and Phytopharm plc), where he was responsible, respectively, for the development of novel small molecules for the treatment of IBS-C & IBS-A and Parkinson’s disease & ALS, taking those assets from pre-clinical development through late-stage clinical trials. Latterly, Nick has worked for the global CRO, PPD Ltd, providing programme management support for biotech and small pharma companies developing small molecule and biologics for the treatment of airway diseases; and most recently with Daiichi Sankyo Development, providing programme management expertise for two products being developed for the treatment of pain indications and a product being developed for the treatment of asthma.

The breadth and depth of Nick’s R&D experience is considerable, spanning CMC, non-clinical, clinical and regulatory. Throughout his career Nick has worked in close collaboration with commercial colleagues and has previously been closely involved in licensing activities, establishing relationships with pharma partners and authoring patent applications/maintaining patent portfolios.

Nick’s industry career was preceded by an academic career as a senior research fellow in virology within the Department of Pathology at the University of Cambridge and with the AFRC Institutes of Animal Health. Nick received his Ph.D in bacterial genetics in 1990, from the University of Cranfield.

Boyd Consultants
Unit M, South Cambridge Business Park,
Babraham Road, Sawston,
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7584 216733
E nick.meyers@boydconsultants.com

Dr Natasha Nesterova-Smith PharmD (Hons), MTOPRA Associate Director, Regulatory Affairs

Natasha is a Regulatory Affairs professional with over 14 years regulatory experience in drug development and registrations for biological and small molecules, including orphan drugs: clinical development, scientific advice and pre-submission meetings, MAA, paediatric investigation plans and lifecycle management for EU centrally approved products. Natasha’s particular experience lies across the therapeutic areas of oncology and transplant (NCE); immunology, enzyme-replacement therapy (biotechnology), HRT, CNS and cardiovascular.

Qualifying at St Petersburg State Academy of Chemistry and Pharmacy, Natasha worked in Russia for a number of years as Head of Hospital Pharmacy and as a Pharmaceutical Consultant. In 2001, Natasha moved to Regulatory Affairs at AMGEN and from there has held Regulatory positions at PAREXEL International, Transkaryotic Therapies (now Shire), Genzyme and more recently at REGEM Consulting as a Regulatory Consultant.

Natasha, a member of TOPRA, brings her expertise in project management to the team at Boyds. She is a confident communicator with regulatory authorities, clients and project team members.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7471 351155.
E natasha.nesterovasmith@boydconsultants.com

 

Dr Jayne Hunt PhD, DipRegAff Associate Director, Regulatory Affairs

Dr Jayne Hunt is a Regulatory Affairs professional with almost 25 years’ experience in both the regulatory product development and post marketing arenas supporting CMC, Non-clinical, Clinical, Labelling and Safety activities, including variations, renewals and other post marketing requirements for biologicals and small molecules within the Ethical, Generic and CRO environments.

Jayne has a wide breadth of development experience in many therapeutic areas in both small (semi-virtual) environment (Phytopharm Plc), larger companies (Merck Generics, Lundbeck, Solvay, Janssen-Cilag, Takeda) as well as CROs (PPD, Parexel).

Jayne began her career in the Pharmacovigilance Department at the MHRA before moving into the Pharmaceutical Industry where she supported Global Phase 1-4 studies and single country / regional submissions, including First in Human INDs. Jayne has coordinated regulatory strategy activities and support for immunology, dermatology, CNS development teams for Europe, North America, Japan, Latin America and other rest of work countries.

Jayne has a BSc and PhD in Biochemistry and has also completed the TOPRA Postgraduate Diploma in Regulatory Affairs.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7341 885732
E jayne.hunt@boydconsultants.com

Dr Kathryn Parsley MPhil, PhD, MTOPRA Associate Director, Regulatory Affairs

Kathryn joined the Regulatory Affairs team at Boyds in March 2018.

Kathryn is a biological science graduate with an MPhil in Microbiology/Immunology, and a PhD in Molecular Immunology/gene therapy. She started her career in anthrax vaccine research, development and GMP manufacture at the Centre for Applied Microbiology and Research (CAMR), UK. Kathryn then progressed to the Institute of Child Health and Great Ormond Street Hospital NHS Trust, UK where she worked for 12 years in the research, development, translation, manufacture and management of gene and cell-based Phase I/II clinical trials. During this time, Kathryn trained as a Clinical Scientist in Immunology/Gene therapy and was registered with the Health Profession Council in the UK.

In 2011, Kathryn moved to PPD and progressed to Senior Manager level where she was Regulatory Affairs Lead for numerous global Phase I-IV studies involving chemical, biological (including vaccines) and Advance Therapies Medicinal Products (ATMP). Indications include prostate and cervical cancer, rheumatoid arthritis, epilepsy and rare diseases such as GM2 gangliosidosis. As a Subject Matter Expert (SME) in gene therapy and Genetically Modified Organisms (GMO’s) products, Kathryn was a key member of the team providing early engagement and product development consultancy to sponsors developing ATMP and GMO products. Kathryn was an active and leading member of the PPD Advanced Therapies forum (AT-Forum) and is a member of the British Society for Cell and Gene Therapy (BSGCT). Kathryn has presented at the BSGCT conference on early stage development of GTMP and co-authored an article on Global regulatory challenges during early stage development of gene therapy medicinal products (GTMP), published in June edition of the Regulatory Rapporteur. Kathryn played a pivotal role in GTMP education internally at PPD and externally, recently presenting on GMO’s at University College London, Regulatory Science for Advanced (Gene and Cell) Therapy: Advanced Therapies – Bench to Medicine course.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 716621
F +44 (0)1270 253832
M +44 (0)7741 630055
E kathryn.parsley@boydconsultants.com

Dr Elaine Harper PhD Cantab, MPhil, BSc, ARCS Associate Director, Programme Management

Dr Elaine Harper has over 25 years of research and development experience in pharmaceutical, biologics and cell and gene therapy arenas working and publishing in a number of therapeutic areas, including oncology, endocrinology, gastroenterology, inflammation and virology.

After completing her PhD and a brief period of post-doctoral research at the Parke Davis Research Unit, Cambridge, Elaine moved into the industry spending 16 years at the James Black Foundation followed by 7 years working in biotech and CRO companies (Syntaxin Ltd and hVIVO). At the James Black Foundation, Elaine led the research and drug discovery activities of a small team of Analytical Pharmacologists and also supervised a number of graduate and PhD students. At Syntaxin, Elaine was initially employed as a preclinical pharmacologist, responsible for identification of and program management of the preclinical activities required for first in man studies of a novel biologic for the treatment of COPD. She then took over as Head of Department and was responsible for leading the research and development activities of the company Pharmacology and Cell Biology scientists, project leadership and strategic planning of project science. As Development Pharmacology sub-team leader, Elaine was also responsible for devising the Pharmacology preclinical plan and subsequently project managing internal and outsourced activities with CRO and national and international collaborators to support the regulatory submission of a novel biologic for the treatment of Acromegaly. At hVIVO, as Cell Biology and Inflammation Target Discovery Team Leader, Elaine worked with a team of cross-disciplinary scientists to identify biomarkers and novel host immunomodulator targets for the treatment of respiratory viral infections leading to exacerbations of asthma and COPD.

Latterly, Elaine worked at the Cell and Gene Therapy Catapult in London where she was responsible for program management of a number of multidisciplinary UK-based and global cell and gene therapy projects focused on assisting cell and gene therapy developers translate research into commercially viable therapies.

Elaine has a wealth of experience in compiling Grant applications, research and development plans and patent applications and has a BSc and Associateship of the Royal College of Science in Biochemistry from Imperial College, London University and MPhil and PhD in Pharmacology from Cambridge University.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7341 885731
E elaine.harper@boydconsultants.com

 

Dr Céline Courtay-Cahen PhD, MTOPRA Senior Manager, Regulatory Affairs

Céline is an experienced researcher with a varied background in Molecular Biology and Cancer Genomics and has used her expertise to develop her career into the Regulatory Affairs field. Céline joined Boyds’ growing Regulatory Affairs Team in May 2016 and manages projects including orphan drug designation, clinical trial applications and marketing authorisation applications.

Céline joins Boyds from Envigo Pharma Consulting Limited where she was a Regulatory Affairs Consultant and worked on gene therapy projects, orphan drug applications, paediatric products, modules 3 and 4 for MAA and pharmacovigilance.

Her expertise includes the writing and review of regulatory documents, providing up-to-date regulatory advice to clients and project management of EU submissions.

Her career has seen her in various research positions at the Institute of Structural Biology in Grenoble; the Faculty of Medicine at the Free University of Brussels; and the Department of Pathology at the University of Cambridge. Céline then went on to join the Molecular Oncology Research Team at the Animal Health Trust in Newmarket where she worked on a study on Canine Cancers. In 2012, she moved into Regulatory Affairs and joined Cambridge Regulatory Services as a Project Manager.

Céline has a Ph.D. from the Faculty of Pharmacy at the University of Nancy in France.

Céline is a member of TOPRA, and is actively involved in the TOPRA SPIN group ‘Young Professionals’.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7789 804042
E celine.courtaycahen@boydconsultants.com

Jonathan Montague BSc, MTOPRA Regulatory Affairs Associate

Jonathan joined Boyds in June 2018 as a Regulatory Affairs Associate. As a member of TOPRA, Jonathan is planning to complete a two-year Regulatory Scientist Apprenticeship alongside building his experience within Boyds working in the regulatory team. His role includes providing operational support for regulatory projects as well as drafting regulatory submission documents, such as clinical trial applications, investigational new drug applications, orphan drug designation applications and other submissions.

Jonathan studied Forensic Science at the University of Central Lancashire, which gave him great exposure across a number of scientific verticals, including chemistry, biology, genetics, toxicology and medicine.

He has experience of working in an Environmental Laboratory and also for the NHS as a Medical Laboratory Assistant/Clinical Trial Assistant in Pathology. Keen to move into a more commercial role, Jonathan joined a Life Sciences recruitment company to focus on Regulatory Affairs positions across Europe. Jonathan spent five years with the business during which time he progressed to become a Senior Consultant and was heavily involved in the development of the organisation from 18 employees to 70 across six offices, including a 12-month period establishing the business in the US. Having built up this experience, Jonathan was keen to return to his scientific routes and joined Boyds to pursue his career in regulatory affairs.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
E jonathan.montague@boydconsultants.com

 

Dr Christine Carrington PhD, MICR Consultant

Dr Christine Carrington is a graduate of Birmingham University, and completed her PhD in Biochemistry and Cell Biology at Reading University in the United Kingdom, followed by ten years of postdoctoral research: in the Dept. of Zoology, Washington State University, and in the Dept. of Clinical Biochemistry and the Dept. of Surgery, Cambridge University. She was then employed by Imutran Ltd, a Novartis Pharma AG company, working in the field of xenotransplantation, initially as Head of the Vascular Biology Group and subsequently as Unit Head of Product Development. During her academic career and her time at Imutran Ltd, Christine published a large number of peer reviewed publications.

In 2001 Dr Carrington moved to Alizyme Therapeutics Ltd, a virtual pharmaceutical company, where she was responsible for all aspects of the development programme for one of Alizyme’s key products, including manufacturing, regulatory, preliminary research, clinical (Phases I – III) and non-clinical studies. Dr Carrington was also involved in due diligence work, outlicensing and contract negotiations for the product and in regulatory, nonclinical, and bioanalytical aspects of Alizyme’s other programmes.

Dr Carrington became a freelance consultant working with Boyd Consultants in January 2010 and is involved in working with European and North American companies developing gene based medicines.
Dr Carrington is an Honorary Senior Lecturer at the University of Birmingham.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7584 517024
E christine.carrington@boydconsultants.com

 

Dr Robin Henderson PhD Regulatory Affairs Consultant

Dr Robin Henderson completed his PhD in biochemistry at Leicester University sponsored by Zeneca BioProducts. After postdoctoral molecular biology and microbial physiology research at Sheffield University he joined Kendle International, bringing his scientific training and biotechnological expertise into a regulatory affairs role.

In 2003 he joined the fledgling Gregory Fryer Associates, providing high level regulatory affairs advice as the Principal Consultant. He performed the role of regulatory lead in the project teams of several small biotechnology companies in the field of cell therapy, gene therapy and protein therapeutics, providing strategic and operational support to advance these products through the clinic and to licensure.

During this time he interacted regularly with EMA, FDA and European Member States regulatory authorities and was lead author of Module 3 and the Quality Overall Summary for the first gene therapy application submitted to EMA.

In 2010 Dr Henderson joined Amgen in the UK where he was responsible for both pipeline and marketed products in the cardio-renal therapeutic area.

Dr Henderson joined Boyd Consultants in September 2011 and provides strategic and operational regulatory support to European and North American companies developing innovative medicines in areas of unmet need.

Dr Henderson is an Honorary Lecturer at Manchester University.

Boyd Consultants
Unit M, South Cambridge Business Park
Babraham Road, Sawston
Cambridgeshire, CB22 3JH
United Kingdom
T +44 (0)1954 252652
F +44 (0)1270 253832
M +44 (0)7557 972192
E robin.henderson@boydconsultants.com

 

 

Dr Bryan Murray MBBS Consultant Medical Advisor

Bryan is an experienced trials physician with 7 years’ experience working on various phase clinical studies as an investigator, principal investigator (PI) level and now as a medical monitor and research physician with Boyds.

Bryan qualified with a Bachelor of Medicine and Bachelor of Surgery in 2007 having been a Nurse in the NHS and private sector for 10 years previously. He has attained further postgraduate training in both pharmacovigilance (Drug Safety Research Unit – PgC in Pharmacovigilance) and pharmaceuticals (Part 1 Dip Pharm Med exam). He started his research career as an investigator and senior Investigator at Retroscreen Virology (now hVIVO) for 5 years where he acted as principle investigator and medical expert for a number of internal and sponsor-led IMP and virus characterisation studies. He then moved into the role of Associate Medical Director providing leadership and direction to medical and clinical study team, whilst ensuring appropriate GCP and regulatory and procedural compliance.

At Boyds, Bryan works as the Consultant Medical Monitor and has worked for studies in the UK, EU and US, gaining a varied therapeutic experience in the clinical development of many investigational medicines from small molecules through to large-IMP biologics and latterly has added experience in the areas orphan designation and ATIMP’s.

T +44 (0)7833 204296
E bryan.murray@boydconsultants.com

 

 

Christine Smith MB, ChB, Dip Pharm Med, FFPM Consultant Pharmaceutical Physician

Christine is an experienced Pharmaceutical Physician with 10 years experience working across all phases of drug development.  

Christine qualified with a Bachelor of Medicine and Bachelor of Surgery in 1999 from the University of the Free State in South Africa and completed her post-graduate Diploma in Pharmaceutical Medicine in 2015 form the University of Brussels.

She moved into the research industry after 4 years of clinical practice, starting in a Phase 1 Contact Research Organisation in London, before moving into the pharmaceutical industry and working as a medical advisor for Organon Laboratories in Cambridge across Phase 2, 3 and 4 clinical trials and active fieldwork. In this role, Christine worked on female hormones, from contraception to IVF and HRT, engaging with academic institutes and key opinion leaders.

From there, she worked in the field of diabetes for Sanofi Aventis and Novo Nordisk before transitioning into medical management – managing a team of 18 MDs and PhDs across the UK and the Channel Islands. Her work was recognised in her being selected as the UK ambassador for the Global Leadership Development program by Novo Nordisk for 2015-2016. Following this, she worked as a Consultant Medical Monitor on studies in the UK, EU and US across various therapeutic fields of many investigational medicines, from small molecules to large IMP-biologics and ATIMPs.

Registered with the GMC, Christine is proficient in statistics, clinical trial design and conduct and has achieved her final ABPI signatory status. She is also a Fellow at the Faculty of Pharmaceutical Medicine.

At Boyds, she works as a Consultant Pharmaceutical Physician,  to support the clinical activities of the company and in particular supporting the work being undertaken in cell and  gene therapy development.

M +44 (0)7958 546132
E christine.smith@boydconsultants.com

Bryan Hurst MPhil, CSci, Hon FICR Consultant

Bryan has spent all of his working life doing academic or industry-sponsored medical/clinical research.

He has almost 30 years experience in drug development starting as a CRA before progressing to global project management. His experience includes all phases of drug development and latterly contributing to the development and operational strategy and project management of major drug developments including Merrem, Seroquel and Crestor.

In addition Bryan has extensive experience in professional development and preparing and delivering training material for clinical research.

Bryan is an Honorary Fellow of the Institute of Clinical Research, a Chartered Scientist and an Honorary Consultant for the University of Manchester.

Bryan has been successfully running his own Project Management and Training Consultancy Company for the last 8 years and for the last 3 years he has worked in close collaboration with Boyd Consultants as a hands-on Project Manager.

Boyd Consultants
Electra House
Crewe Business Park
Crewe, Cheshire
CW1 6GL
T +44 (0)1270 270010
F +44 (0)1270 253832
M +44 (0)7881 780249
E bryan.hurst@boydconsultants.com

Sue Carr PR & Marketing Communications

Sue is an experienced marketer with a strong track record working with companies in the life sciences, clean tech, professional and business services sectors. Her past experience includes Head of National Marketing at Tenon and more recently Marketing Director at Berryman (now Shakespeares). She is now director of V Formation Ltd based in BioCity Nottingham, and works with Boyds providing marketing communications and PR support and advice.

T +44 (0)1270 270010
F +44 (0)1270 253832
M +44 (0)7809 727533
E sue@vformation.biz